title: Wales approves new hepatitis C drug while England deliberates.
authors.affiliation: Bath.
authors.forename: Piotr
authors.initials: P
authors.lastname: Ozieranski
authors.affiliation: Cambridge.
authors.forename: Lawrence
authors.initials: L
authors.lastname: King
mesh_terms: D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D002219:Carbamates / Q000191:economics / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D004739:England; D006526:Hepatitis C / Q000188:drug therapy* / Q000191:economics; D006576:Heterocyclic Compounds, 4 or More Rings / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D000069474:Sofosbuvir / Q000191:economics / Q000627:therapeutic use*; D013222:State Medicine / Q000191:economics; D014852:Wales
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D004338:Drug Combinations; D006576:Heterocyclic Compounds, 4 or More Rings; C000611331:sofosbuvir-velpatasvir drug combination; D000069474:Sofosbuvir